In addition, targeting ligands, such as TF, aptamer, and antibody fragments, can also be applied onto m‐srNPs to further enhance clinical anti‐tumor efficacy through realizing a vectored drug delivery toward cancers.[244] This site‐specific cancer targeting and fast drug release system would become a highly appealing aspect for future efforts because m‐srNPs significantly improved bio‐distribution and pharmacokinetics of anti‐tumor drugs, thus offering the potential therapeutic effect with decreasing side effects in vivo.[245]. The gene discussed is TF; the disease is cancer.